Silvia Brugiapaglia
YOU?
Author Swipe
View article: The absence of IL17A favours cytotoxic cell function and improves antigen‐specific immunotherapies in pancreatic adenocarcinoma
The absence of IL17A favours cytotoxic cell function and improves antigen‐specific immunotherapies in pancreatic adenocarcinoma Open
Background and Aims The pancreatic tumour microenvironment (TME) is a complex ecosystem where tumour cells, cancer‐associated fibroblasts and immune cells interact, often in ways that contribute to tumour growth. The role of interleukin (I…
View article: Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier
Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier Open
Pancreatic ductal adenocarcinoma (PDA) is a highly challenging malignancy to treat, with a high mortality rate and limited therapeutic options. Despite advances in cancer research, the prognosis for patients diagnosed with PDA is often poo…
View article: Anti-Cancer Drugs: Trends and Insights from PubMed Records
Anti-Cancer Drugs: Trends and Insights from PubMed Records Open
Background: In recent years, there has been an exponential growth in global anti-cancer drug research, prompting the necessity for comprehensive analyses of publication output and thematic shifts. Methods: This study utilized a comprehensi…
View article: Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?
Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? Open
Pancreatic adenocarcinoma (PDA) represents the fourth leading cause of cancer-related mortality in the USA. Only 20% of patients present surgically resectable and potentially curable tumors at diagnosis, while 80% are destined for poor sur…
View article: In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens
In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens Open
Introduction Pancreatic Ductal Adenocarcinoma (PDA) is one of the most aggressive malignancies with a 5-year survival rate of 13%. Less than 20% of patients have a resectable tumor at diagnosis due to the lack of distinctive symptoms and r…
View article: PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer
PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer Open
View article: Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival
Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival Open
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis due to a lack of early diagnostic markers and effective therapy. In PDA patients, the glycolytic enzyme and plasminogen receptor alpha-enolase (ENO1) and the transcription facto…
View article: <i>HLA‐DPB1*13:01</i> associates with enhanced, and <i>KIR2DS4*001</i> with diminished protection from developing severe <scp>COVID</scp>‐19
<i>HLA‐DPB1*13:01</i> associates with enhanced, and <i>KIR2DS4*001</i> with diminished protection from developing severe <span>COVID</span>‐19 Open
Extreme polymorphism of HLA and killer‐cell immunoglobulin‐like receptors (KIR) differentiates immune responses across individuals. Additional to T cell receptor interactions, subsets of HLA class I act as ligands for inhibitory and activa…
View article: Functional and transcriptome analysis of peripheral blood lymphocytes in pancreatic cancer patients before and after chemotherapy
Functional and transcriptome analysis of peripheral blood lymphocytes in pancreatic cancer patients before and after chemotherapy Open
Pancreatic Ductal Adenocarcinoma (PDA) is one of the most aggressive malignancies with a 5-year survival rate of 11% due to its high resistance to chemotherapy (CT). Understanding how to better induce an effector response following tumor a…
View article: 1318 A next generation DNA vaccine coding for the immunodominant sequence of alpha-enolase with enhanced ability to induce effector T cell responses to cure pancreatic cancer
1318 A next generation DNA vaccine coding for the immunodominant sequence of alpha-enolase with enhanced ability to induce effector T cell responses to cure pancreatic cancer Open
Background Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies with a 5-year survival rate of 11%.1 Only the 15% of patients have a resectable disease eligible for surgical resection followed by adj…
View article: 1429 Immune receptor PIRB deletion impacts pancreatic cancer growth and anti-tumor immune response
1429 Immune receptor PIRB deletion impacts pancreatic cancer growth and anti-tumor immune response Open
Background Paired immunoglobulin-like receptor B (PIRB), the murine ortholog of human leukocyte immunoglobulin-like receptor B 2 and 3 (LILRB2/3), is an inhibitory receptor expressed on the surface of macrophages, granulocytes, dendritic c…
View article: The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer
The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of human cancer, characterized by unrestrained progression, invasiveness and treatment resistance. To date, there are limited curative options, with surgical resection …
View article: 471 Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition
471 Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition Open
Background Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer mortality in developed countries, with one of the poorest prognoses among all cancers. Although 10–15% of patients are candidates for gross total surgical…
View article: The dark side of immunotherapy: pancreatic cancer
The dark side of immunotherapy: pancreatic cancer Open
Since the journal Science deemed cancer immunotherapy as the "breakthrough of the year" in 2014, there has been an explosion of clinical trials involving immunotherapeutic approaches that, in the last decade - thanks also to the ren…